Keywords: Amgen, Second-quarter 2010 finacnial results
Amgen sees flat 2nd-qtr 2010 earnings as Aranesp sales slump
Article | 02 August 2010
Global biotechnology leader Amgen reported adjusted earnings per share of $1.38 for the second quarter of 2010, an increase of 7%. However, adjusted ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
